Ā | Use of GCs | Ā | No use of GCs | Ā |
---|---|---|---|---|
Ā | GC-S (n= 24) | GC-I (n= 13) | GC-S (n= 44) | GC-I (n= 15) |
Age at delivery in years, mean (SD) | 34.1 (3.1) | 34.1 (3.6) | 31.6 (3.9) | 31.2 (3.0) |
Disease duration in years, median (range) | 4.6 (0.2-28.6) | 6.8 (1.0-22.7) | 5.3 (0.1-28.5) | 2.4 (0.2-28.4) |
Gestational age at delivery in weeks, mean (SD) | 39.0 (1.9)A | 37.4 (2.2) | 39.8 (1.3) | 39.9 (1.3) |
Anti-CCP positive, n (%) | 16 (66.7) | 8 (61.5) | 24 (54.5) | 6 (40%) |
Rheumatoid factor (IgM) positive, n (%) | 17 (70.8) | 10 (76.9) | 31 (70.5) | 9 (60.0) |
Presence of erosions, n (%) | 22 (91.7) | 13 (100) | 28 (63.6) | 8 (53.3) |
Dosage of prednisone (pregnancy; mg/day), median (range) | 6.25 (2.5-15) | 8.75 (5-20) | - | - |
Dosage of prednisone (postpartum; mg/day), median (range) | 8.75 (2.5-15) | 10.0 (5-15) | - | - |
Number of DMARDs before conception, median (range) | 2 (0-4) | 2 (1-5) | 2 (0-4) | 2 (0-3) |
Moderate/good response during pregnancy, n (%) | 5/11 (45.5) | 4/9 (44.4) | 8/16 (50) | 5/11 (45.5) |
Very early flare, N/Ntotal (%) | 5/21 (23.8) | 3/13 (23.1) | 10/41 (24.4) | 5/13 (38.5) |
Early flare, N/Ntotal (%) | 4/21 (19.0) | 2/12 (16.7) | 12/40 (30.0) | 3/13 (23.1) |
Late flare, N/Ntotal (%) | 4/19 (21.1) | 4/13 (30.8) | 15/37 (40.5) | 4/12 (33.3) |
Breastfeeding (6 weeks postpartum), n (%) | 8 (33.3) | 1 (7.7) | 20 (45.5) | 8 (53.3) |
Use of NSAIDs at 6 months postpartum,a N/Ntotal (%) | 7/22 (31.8)b | 10/13 (76.9) | 13/40 (32.5) | 6/13 (46.2) |
Use of MTX at 6 months postpartum,a N/Ntotal (%) | 11/22 (50.0) | 9/13 (69.2) | 10/40 (25.0) | 5/13 (38.5) |
Use of sulfasalazine at 6 months postpartum,a N/Ntotal (%) | 6/22 (27.3) | 2/13 (15.4) | 17/40 (42.5) | 6/13 (46.2) |
Use of anti-TNF-Ī± at 6 months postpartum,a N/Ntotal (%) | 3/22 (13.6) | 3/13 (23.1) | 2/40 (5.0) | 0/13 (0) |